Literature DB >> 27403287

Controversy Surrounding ROCKET-AF: A Call for Transparency, But Should We Be Changing Practice?

Jason D Matos1, Peter J Zimetbaum2.   

Abstract

Year:  2016        PMID: 27403287      PMCID: PMC4939307          DOI: 10.15420/aer.2016.24.2

Source DB:  PubMed          Journal:  Arrhythm Electrophysiol Rev        ISSN: 2050-3369


× No keyword cloud information.
  14 in total

1.  Rivaroxaban: can we trust the evidence?

Authors:  Deborah Cohen
Journal:  BMJ       Date:  2016-02-03

2.  Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939--an oral, direct Factor Xa inhibitor--after multiple dosing in healthy male subjects.

Authors:  Dagmar Kubitza; Michael Becka; Georg Wensing; Barbara Voith; Michael Zuehlsdorf
Journal:  Eur J Clin Pharmacol       Date:  2005-11-17       Impact factor: 2.953

3.  Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.

Authors:  Harry R Büller; Martin H Prins; Anthonie W A Lensin; Hervé Decousus; Barry F Jacobson; Erich Minar; Jaromir Chlumsky; Peter Verhamme; Phil Wells; Giancarlo Agnelli; Alexander Cohen; Scott D Berkowitz; Henri Bounameaux; Bruce L Davidson; Frank Misselwitz; Alex S Gallus; Gary E Raskob; Sebastian Schellong; Annelise Segers
Journal:  N Engl J Med       Date:  2012-03-26       Impact factor: 91.245

4.  Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation.

Authors:  Riccardo Cappato; Michael D Ezekowitz; Allan L Klein; A John Camm; Chang-Sheng Ma; Jean-Yves Le Heuzey; Mario Talajic; Maurício Scanavacca; Panos E Vardas; Paulus Kirchhof; Melanie Hemmrich; Vivian Lanius; Isabelle Ling Meng; Peter Wildgoose; Martin van Eickels; Stefan H Hohnloser
Journal:  Eur Heart J       Date:  2014-09-02       Impact factor: 29.983

5.  Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial.

Authors:  Renato D Lopes; Sana M Al-Khatib; Lars Wallentin; Hongqiu Yang; Jack Ansell; M Cecilia Bahit; Raffaele De Caterina; Paul Dorian; J Donald Easton; Cetin Erol; Justin A Ezekowitz; Bernard J Gersh; Christopher B Granger; Stefan H Hohnloser; John Horowitz; Elaine M Hylek; John J V McMurray; Puneet Mohan; Dragos Vinereanu; John H Alexander
Journal:  Lancet       Date:  2012-10-02       Impact factor: 79.321

6.  Gastrointestinal Bleeding in Patients With Atrial Fibrillation Treated With Rivaroxaban or Warfarin: ROCKET AF Trial.

Authors:  Matthew W Sherwood; Christopher C Nessel; Anne S Hellkamp; Kenneth W Mahaffey; Jonathan P Piccini; Eun-Young Suh; Richard C Becker; Daniel E Singer; Jonathan L Halperin; Graeme J Hankey; Scott D Berkowitz; Keith A A Fox; Manesh R Patel
Journal:  J Am Coll Cardiol       Date:  2015-12-01       Impact factor: 24.094

7.  Dabigatran versus warfarin in patients with atrial fibrillation.

Authors:  Stuart J Connolly; Michael D Ezekowitz; Salim Yusuf; John Eikelboom; Jonas Oldgren; Amit Parekh; Janice Pogue; Paul A Reilly; Ellison Themeles; Jeanne Varrone; Susan Wang; Marco Alings; Denis Xavier; Jun Zhu; Rafael Diaz; Basil S Lewis; Harald Darius; Hans-Christoph Diener; Campbell D Joyner; Lars Wallentin
Journal:  N Engl J Med       Date:  2009-08-30       Impact factor: 91.245

8.  Edoxaban versus warfarin in patients with atrial fibrillation.

Authors:  Robert P Giugliano; Christian T Ruff; Eugene Braunwald; Sabina A Murphy; Stephen D Wiviott; Jonathan L Halperin; Albert L Waldo; Michael D Ezekowitz; Jeffrey I Weitz; Jindřich Špinar; Witold Ruzyllo; Mikhail Ruda; Yukihiro Koretsune; Joshua Betcher; Minggao Shi; Laura T Grip; Shirali P Patel; Indravadan Patel; James J Hanyok; Michele Mercuri; Elliott M Antman
Journal:  N Engl J Med       Date:  2013-11-19       Impact factor: 91.245

9.  Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation.

Authors:  Riccardo Cappato; Francis E Marchlinski; Stefan H Hohnloser; Gerald V Naccarelli; Jim Xiang; David J Wilber; Chang-Sheng Ma; Susanne Hess; Darryl S Wells; George Juang; Johan Vijgen; Burkhard J Hügl; Richard Balasubramaniam; Christian De Chillou; D Wyn Davies; L Eugene Fields; Andrea Natale
Journal:  Eur Heart J       Date:  2015-05-14       Impact factor: 29.983

10.  XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation.

Authors:  A John Camm; Pierre Amarenco; Sylvia Haas; Susanne Hess; Paulus Kirchhof; Silvia Kuhls; Martin van Eickels; Alexander G G Turpie
Journal:  Eur Heart J       Date:  2015-09-01       Impact factor: 29.983

View more
  1 in total

Review 1.  Review Article: Gastrointestinal Bleeding Risk with Direct Oral Anticoagulants.

Authors:  Robert Benamouzig; Maxime Guenoun; David Deutsch; Laurent Fauchier
Journal:  Cardiovasc Drugs Ther       Date:  2021-06-18       Impact factor: 3.947

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.